Use of GLP-1 Medicines in Primary Care: Preparedness, Fair Access, and the Risk of Unequal Obesity Treatment

Glucagon-like peptide-1 receptor agonists may lead to substantial weight loss and reduced major cardiovascular events in patients with established cardiovascular disease.

• Integration of these therapies into primary care is hindered by provider training gaps and clinical inertia.
• Disparities exist in the prescription and use of these medications among racial and ethnic minority groups and low-income communities.
• Patients with public insurance are less likely to receive or fill prescriptions for obesity treatment.
• Without coordinated action, the availability of these therapies may create inequities based on socioeconomic status.
• Achieving equitable access may require reforms in insurance coverage, treatment costs, and primary care practices.

Simplified